Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$13.44

-0.037%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$92.12M
EPS-70.5000
P/E Ratio-0.19
Earnings Date08/11/2026

vor

Cash and Short Term Investments

Last Annual Value

455.21M

3-Year CAGR

26%

5-Year CAGR

56%

10-Year CAGR

86%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Cash and Short Term Investments

VOR · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
455.21M
49.2%17.0%N/A 
76.96M
27.5%12.9%9.4%
40.27M
-19.2%-22.8%14.6%
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
78.21M
6.3%-7.7%15.1%
172.12M
13.5%-16.2%3.3%
163.94M
98.7%10.9%27.0%
14.60M
-14.3%26.6%N/A
46.63M
-16.6%-21.6%-0.9%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
54.02M
-14.7%N/AN/A
106.51M
6.7%57.8%N/A
155.55M
33.4%11.3%14.2%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.44, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $13.44